ALIBERTI, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 10.277
EU - Europa 4.174
AS - Asia 4.057
SA - Sud America 756
AF - Africa 73
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.356
Nazione #
US - Stati Uniti d'America 10.031
SG - Singapore 1.463
CN - Cina 1.170
HK - Hong Kong 768
RU - Federazione Russa 720
DE - Germania 715
BR - Brasile 617
SE - Svezia 594
UA - Ucraina 535
IE - Irlanda 469
IT - Italia 451
VN - Vietnam 283
GB - Regno Unito 202
CA - Canada 199
FI - Finlandia 127
AT - Austria 111
FR - Francia 97
IN - India 75
AR - Argentina 60
KR - Corea 44
BD - Bangladesh 42
ID - Indonesia 38
NL - Olanda 37
JP - Giappone 35
ZA - Sudafrica 33
MX - Messico 29
TR - Turchia 28
CZ - Repubblica Ceca 25
EC - Ecuador 22
PL - Polonia 21
IQ - Iraq 20
CO - Colombia 17
DK - Danimarca 17
PK - Pakistan 14
BE - Belgio 13
ES - Italia 13
VE - Venezuela 11
PY - Paraguay 9
AU - Australia 8
EG - Egitto 8
NZ - Nuova Zelanda 8
PE - Perù 8
SA - Arabia Saudita 8
CL - Cile 7
MA - Marocco 7
UZ - Uzbekistan 6
BG - Bulgaria 5
IR - Iran 5
KE - Kenya 5
KZ - Kazakistan 5
NP - Nepal 5
TH - Thailandia 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
CH - Svizzera 4
DZ - Algeria 4
JO - Giordania 4
LB - Libano 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
HN - Honduras 3
IL - Israele 3
KH - Cambogia 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
SN - Senegal 3
TW - Taiwan 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GR - Grecia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LT - Lituania 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
RO - Romania 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
CG - Congo 1
CM - Camerun 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
TJ - Tagikistan 1
Totale 19.356
Città #
Ann Arbor 1.381
Woodbridge 1.161
Fairfield 865
Singapore 799
Houston 775
Hong Kong 765
Ashburn 684
Jacksonville 565
Dublin 458
Chandler 456
Wilmington 366
Seattle 352
Dearborn 346
Cambridge 302
Frankfurt am Main 253
New York 233
Beijing 230
Princeton 225
Milan 123
Nanjing 119
Santa Clara 116
Los Angeles 113
Hangzhou 110
Altamura 108
Lachine 97
Vienna 97
Shanghai 96
Lawrence 95
Dallas 89
The Dalles 83
Moscow 81
Ho Chi Minh City 77
Chicago 60
Hefei 59
Buffalo 56
São Paulo 53
Hanoi 50
Nanchang 46
Seoul 41
San Diego 39
Shenyang 34
Ottawa 31
Dong Ket 30
Hebei 29
Toronto 29
Munich 27
Jiaxing 26
Rio de Janeiro 25
Guangzhou 24
Jakarta 24
Brno 23
Andover 22
Council Bluffs 22
Jinan 22
Norwalk 22
Salt Lake City 22
Tianjin 21
Changsha 20
Falls Church 20
Helsinki 20
London 20
Tokyo 18
Boardman 17
Ningbo 17
Mountain View 16
Warsaw 16
Fremont 15
Rome 15
Brooklyn 14
Huizen 14
Atlanta 13
Belo Horizonte 13
Dhaka 13
Montreal 13
Redondo Beach 12
Tampa 12
Brussels 11
Columbus 11
Kunming 11
Phoenix 11
Denver 10
Quito 10
Zhengzhou 10
Curitiba 9
Guarulhos 9
Mexico City 9
Miami 9
San Francisco 9
Stockholm 9
Beauharnois 8
Cotia 8
Johannesburg 8
Lissone 8
Manchester 8
Nuremberg 8
Orem 8
San Jose 8
Amsterdam 7
Boston 7
Brasília 7
Totale 12.968
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 373
Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia 328
Impact of age and comorbidity on cause and outcome in community-acquired pneumonia 276
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases 270
Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: Do we need a personalized approach? 264
Impact of traffic-related air pollution on pulmonary oxidative stress 263
Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia 262
Dyspnea in crackling lungs 260
Influenza A/H1N1 severe pneumonia: Novel morphocytological findings in bronchoalveolar lavage 254
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 254
Clinical phenotypes in adult patients with bronchiectasis 251
Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts 247
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients 237
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia 227
A 13-year-old female with shortness of breath and pleuritic chest pain 224
A 61-year-old female with chronic cough and purulent sputum 224
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study 222
Phenotyping in Bronchiectasis: Are we moving towards a personalized medicine? 222
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 220
Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis 219
Prulifloxacin: A brief review of its potential in the treatment of acute exacerbation of chronic bronchitis 217
Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity 217
Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study 208
Mortality in acute cardiogenic pulmonary edema treated with continuous positive airway pressure 207
Mixed community-acquired lower respiratory tract infections 203
The management of community-acquired pneumonia in the elderly 202
Hospital admission decision for patients with community-acquired pneumonia 201
Geriatric multidimensional assessment for elderly patients with acute respiratory diseases 200
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study 200
Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study 200
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 198
Non-invasive continuous positive airway pressure in monolateral lung transplant patient with pneumonia and IPF 194
The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia 194
Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia 192
Individualizing duration of antibiotic therapy in community-acquired pneumonia 192
Chlamydia pneumoniae and acute aortic syndrome: A call for a multi-institutional study 189
Acute myocardial infarction versus other cardiovascular events in communityacquired pneumonia 185
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia 184
Strategic targets of essential host-pathogen interactions 182
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy 182
Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia 182
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia? 182
Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes 179
Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines 179
Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia 178
Pneumonia: how important are local epidemiology and smoking habits? 177
Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates 176
Chlamydophila pneumoniae 176
100 years of respiratory medicine: pneumonia 175
Compliance with anti-H1N1 vaccine among healthcare workers and general population 174
Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward 173
The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients 172
Do prognostic factors help physicians in predicting legionellosis' respiratory complications? 172
Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure 170
Criteria for clinical stability in hospitalised patients with community-acquired pneumonia 170
Azithromycin and lower respiratory tract infections 168
Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis 168
The bronchiectasis severity index. An international derivation and validation study 167
COPD and bronchiectasis: Phenotype, endotype or co-morbidity? 166
Early application of non-invasive continuous positive airway pressure in acute respiratory distress syndrome due to a drug overdose: a case report 165
Should health care systems and health care providers implement a new pathway for hospitalized patients with community-acquired pneumonia? 165
Validation of the 3CPO-score in a prospective cohort of Acute Cardiogenic Pulmonary Edema (ACPE) patients 165
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia 163
Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores 163
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study 162
The role of biomarkers in low respiratory tract infections 162
Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia 161
Antibiotics as immunomodulant agents in COPD 161
Impact of exacerbations in the natural course of COPD 161
Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection 157
Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia 156
Clinical and economical impact of exacerbations of chronic obstructive pulmonary disease (COPD): a two year study 154
Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia 153
Non-invasive-ventilation in H1N1 acute respiratory failure in emergency department: A case series 153
Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia 150
Acute myocardial infarction in hospitalized patients with community-acquired pneumonia 150
The management of patients with community-acquired pneumonia beyond antibiotic therapy 150
Is it time for a "pneumo-geriatrician" for frail old patients with respiratory diseases? 150
Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia 146
Telithromycin in lower respiratory tract infections 146
Acute exacerbation of COPD: application of evidence-based guidelines 146
Management of nontuberculous mycobacterial infection in the elderly 146
Where are the acutely ill best cared for and who should look after them? 145
Cardiac diseases complicating community-acquired pneumonia 144
Pneumococcal Vaccine and Patients with Pulmonary Diseases 142
Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia 141
Highlights on the appropriate use of fluoroquinolones in respiratory tract infections 140
Chlamydia pneumoniae and Mycoplasma pneumoniae 140
Clinical applications of azithromycin microspheres in respiratory tract infections 139
Healthcare-associated pneumonia: where do we go next? 138
The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia 138
Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia 138
“Normotension” on admission to the emergency department affects outcome of patients with acute cardiogenic pulmonary edema (ACPE) 136
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia 131
Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia 128
Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial 127
Acute effects of positive end-expiratory pressure on left ventricle diastolic function in healthy subjects 127
Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice 124
Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective 120
Clinical failure in hospitalized patients with community acquired pneumonia (CAP): Preliminary results from the FAILCAP study 118
Totale 18.349
Categoria #
all - tutte 69.587
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.587


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021927 0 0 0 0 0 82 145 139 146 219 69 127
2021/20221.059 51 102 104 90 52 103 55 61 64 86 93 198
2022/20231.833 250 532 224 133 92 315 9 90 133 4 25 26
2023/20241.249 35 32 47 31 172 335 254 57 153 15 10 108
2024/20252.827 205 348 76 141 275 60 82 79 313 474 326 448
2025/20263.740 694 427 579 905 810 325 0 0 0 0 0 0
Totale 19.589